Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Sangamo BioSciences Inc. Stories

2014-03-20 20:21:58

RICHMOND, Calif., March 20, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the pricing of an underwritten public offering of common stock consisting of 4,444,444 shares at a public offering price of $22.50 per share. The gross proceeds to Sangamo from the public offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In connection with this offering, Sangamo...

2014-03-19 16:23:47

RICHMOND, Calif., March 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that it has commenced a $100 million underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by Sangamo. Sangamo intends to grant the underwriters a 30 day option to purchase up to 15% of the number of shares of common stock sold in the offering. Sangamo intends to use the proceeds from this offering for working capital and...

2014-03-06 12:28:29

Company Outlines Future Plans for HIV "Functional Cure" RICHMOND, Calif., March 6, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the presentation of data from its SB-728-T program to develop a 'functional cure' for HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections (CROI 2014). The conference is being held in Boston from March 3 to 6, 2014. Data from an earlier Phase 1 clinical study in this program were also published in the March 6,...

2014-03-05 16:26:40

Treatment with Sangamo's ZFN- Modified T-cells (SB-728-T) Provides Functional Control of HIV without Antiretroviral Drugs RICHMOND, Calif., March 5, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication in the New England Journal of Medicine of the first clinical study of its proprietary zinc finger nuclease (ZFN)-based genome editing technology in humans. Data from the study, carried out in HIV-positive subjects, demonstrate that the T-cell...

2014-02-26 16:29:37

RICHMOND, Calif., Feb. 26, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(® )development programs and an overview of the company's business strategy at 8:00 am ET on Wednesday March 5, 2014, at the Cowen and Company 34th Annual Health Care Conference which will be held in Boston....

2014-02-11 16:25:42

Significant Clinical and Preclinical Data Presentations in Fourth Quarter of 2013 Highlight Transformational Year RICHMOND, Calif., Feb. 11, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2013 financial results and accomplishments. (Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO) For the fourth quarter ended December 31, 2013, Sangamo reported a consolidated net loss of $8.1 million, or $0.13 per share, compared to a net...

2014-02-06 16:28:01

RICHMOND, Calif., Feb. 6, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(® )development programs and an overview of the company's business strategy at 10:45 am ET on Thursday, February 13, 2014, at the 2014 Leerink Swann Global Healthcare Conference which will be held in New York City. (Logo:...

2014-02-04 20:23:37

RICHMOND, Calif., Feb. 4, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2013 financial results on Tuesday, February 11, 2014, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters....

2014-01-14 12:26:25

CHICAGO, Jan. 14, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Sangamo BioSciences, Inc. (Nasdaq:SGMO-Free Report), Biogen Idec (Nasdaq:BIIB-Free Report), Shire (Nasdaq:SHPG-Free Report), Actelion (OTC:ALIOF-Free Report) and eHealth, Inc. (Nasdaq:EHTH-Free Report)....

2014-01-09 08:27:09

RICHMOND, Calif., Jan. 9, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) will host a teleconference at 8:30 am ET today, Thursday, January 9, 2014, to discuss its global collaboration with Biogen Idec to develop ZFP Therapeutics for hemoglobinopathies. (Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO) A live webcast of the call can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and...